A panel of pathologists, clinical researchers, industry representatives, regulators and patient advocates will address burning topics such as critical issues in drug and biomarker development, comparative effectiveness research and the translation of findings of clinical trials into daily practice. The conference will also discuss and debate the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.